Current treatment practice for essential thrombocythaemia in adults

Bibliography

• PEARSON TC: Primary thrombocythaemia: diagnosis and management. Br. J. Haematol. (1991) 78:145–148.
   PubMed Web of Science ®Google Scholar
• GENDEREN VAN Pll, MICHIELS JJ: Primary thrombo-cythemia: diagnosis, clinical manifestations and management. Ann. Hematol. (1993) 67:57–62.
   PubMedGoogle Scholar
• MICHIELS JJ, KUTTI J, STARK P et al.: Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis. Neth. J. Med. (1999) 54:46–62.
   PubMed Web of Science ®Google Scholar
• MURPHY S, PETERSON P, ILAND H, LASZLO J: Experienceof the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival and leukemic transition by treatment. Semin. Hematol. (1997) 34:29–39.
   PubMed Web of Science ®Google Scholar
• BELLUCCI S, JANVIER M, TOBELEM G et al: Essential thrombocythemias: Clinical evolutionary and biological data. Cancer (1986) 58:2440–2447.
   PubMed Web of Science ®Google Scholar
• CORTELAZZO S, VIERO P, FINAZZI G et al.: Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. Clin. Oncol (1990) 8:556–562.
   Google Scholar
• GUGLIOTTTA L, MARCHIOLI R, FIACCHINI M et al: Epidemiological, diagnostic, therapeutic and prognostic aspects of essential thrombocythemia in a retrospective study of the GIMMC group in two thousand patients. Blood (1997) 90 (Suppl. 1):358a.
   Google Scholar
• MITUS AJ, BARBUI T, SHULMAN LN et al.: Hemostatic complications in young patients with essential thrombocythemia. Am. J. Med. (1990) 88:371–375.
   PubMed Web of Science ®Google Scholar
• RANDI ML, FABRIS F, GIROLAMI A: Thrombocytosis in young people: evaluation of 57 cases diagnosed before the age of 40. Blut (1990) 60:233–237.
   PubMedGoogle Scholar
• HEHLMANN R, JAHN M, BAUMANN B, KOPCKE W: Essential thrombocythemia: clinical characteristics and course of 61 cases. Cancer (1988) 61:2487–2496.
   PubMed Web of Science ®Google Scholar
• FENAUX P, SIMON M, CAULIER MT et al: Clinical courseof essential thrombocythemia in 147 cases. Cancer (1990) 66:549–556.
   PubMed Web of Science ®Google Scholar
• COLOMBI M, RADAELLI F, ZOCCHI L, MAIOLO AT: Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer (1991) 67:2926–2930.
   Google Scholar
• GENDEREN VAN PR MICHIELS JJ: Erythromelalgic, thrombotic and hemorrhagic manifestations in thrombocythemia. Presse Med. (1994) 23:73–77.
   PubMedGoogle Scholar
• BESSES C, CERVANTES F, PEREIRA A eta].: Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia (1999) 13:150–154.
   Google Scholar
• GRIESSHAMMER M, GISSLINGER H, GRÜNEWALD M et al: Hemorrhagic complications in 444 patients with essential thrombocythemia (ET). Blood (1999) 94 (Suppl. 1) Abstract 65, 18a.
   Google Scholar
• GENDEREN VAN PJJ, BUDDE U, MICHIELS JJ, VAN STRIKR, VAN VLIET HHDM: The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count. Br. Haematol. (1996) 93:962–965.
   PubMedGoogle Scholar
• GENDEREN VAN PJJ, MULDER PGH, WALEBOER M, VANDE MOESDIJK D, MICHIELS JJ: Prevention and treatment of thrombotic complications in essential thrombo-cythaemia: efficacy and safety of aspirin. Br. J. Haematol. (1997) 97:179–184.
   PubMedGoogle Scholar
• MICHIELS JJ, VAN GENDEREN PJ, JANSEN PH, KOUDSTAAL PJ: Atypical transient ischemic attacks in thrombocythaemia of various myeloproliferative disorders. Leuk. Lymphoma (1996) 22 (Suppl. 1):65–70.
   Google Scholar
• MICHIELS JJ, VAN GENDEREN PJJ, LINDEMANS J, VAN VLIET HHDM: Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombo-cythemia. Leuk. Lymphoma (1996) 22 (Suppl. 0:47–56.
   Google Scholar
• MICHIELS JJ, KOUDSTAAL PJ, MULDER AH, VAN VLIET HHDM: Transient neurologic and ocular manifesta-tions in primary thrombocythemia. Neurology (1993) 43:1107–1110.
   PubMed Web of Science ®Google Scholar
• RUGGERI M, FINAZZI G, TOSETTO A et al.: No treatmentfor low-risk thrombocythaemia: results from a prospective study. Br. J. Haematol. (1998) 103:772–777.
   PubMed Web of Science ®Google Scholar
• ROZMAN C, GIRALT M, FELIU E, RUBIO D, CORTES MT: Life expectancy of patients with chronic non-leukemic myeloproliferative disorders. Cancer (1991) 67:2658–2663.
   PubMed Web of Science ®Google Scholar
• BARBUI T, FINAZZI G, DUPUY E, KILADJIAN JJ, BRIERE J: Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers. Leuk. Lymph. (1996) 22 (Suppl. 0:149–160.
   Google Scholar
• LAHUERTA-PALACIOS JJL, BORNSTEIN R, FERNANDEZ-DEBORA FJ et al.: Controlled and uncontrolled thrombocytosis. Its clinical role in thrombocythemia. Cancer (1988) 61:1207–1212.
   Google Scholar
• CORTELAZZO S, FINAZZI G, RUGGERI M et al.: Hydroxyurea for patients with essential thrombo-cythemia and a high risk of thrombosis. N Engl. J. Med. (1995) 332:1132–1136.
   PubMed Web of Science ®Google Scholar
• BUDDE U, SCHARF RE, FRANKE P eta].: Elevated plateletcount as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood (1993) 82:1749–1759.
   Google Scholar
• PEARSON TC, BAREFORD D, CRAIG J et al.: The manage-ment of low-risk and intermediate-risk patients with primary thrombocythaemia. Br. J Haematol. (1999) 106:833.
   PubMedGoogle Scholar
• BARBUI T, FINAZZI G: Clinical parameters fordeterming when and when not to treat essential thrombocythemia. Semin. Hematol. (1999) 36(1 Suppl. 2):14–18.
   Google Scholar
• SCHAFER Al: Bleeding and thrombosis in the myeloproliferative disorders. Blood (1984) 64:1–12.
   PubMedGoogle Scholar
• WEINLICH G, SCHULER G, GREIL R, KOFLER H, FRITSCH P: Leg ulcers associated with long-term hydroxyurea therapy. J. Am. Acad. Dermatol. (1998) 39:372–374.
   PubMedGoogle Scholar
• SIRIEIX ME, DEBURE C, BAUDOT N et al.: leg ulcers and hydroxyurea. Arch. Dermatol (1999) 135:818–820.
   PubMed Web of Science ®Google Scholar
• WEINFELD A, SWOLIN B, WESTIN J: Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur. Haematol. (1994) 52:134–139.
   PubMed Web of Science ®Google Scholar
• NAND S, STOCK W, GODWIN J, FISHER SG: lzukemo-genic risk of hydroxyurea therapy in polycythaemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Am. J Hematol (1996) 52:42–46.
   PubMed Web of Science ®Google Scholar
• STERKERS Y, PREUDHOMME C, LAI JL et al.: Acutemyeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood (1998) 91:616-622. Exp. Opin. Pharmacother. (2001) 2(3)
   Google Scholar
• BOIVIN P: Indications, procedure and results for the treatment of polycythaemia vera by bleeding, pipobroman and hydroxyurea. Nouv. Rev. Fr. Hematol. (1993) 35:491–498.
   PubMedGoogle Scholar
• NAIMAN A, STACHOWIAK J, PARLIER Y, GORIN NC, DUHAMEL G: Pipobroman therapy of Polycythaemia vera. Blood (1982) 59:890–894.
   PubMedGoogle Scholar
• NAJEAN Y, DRESCH C, RAIN JD: Intermediary analysis of a French protocol of treatment of polycythemias (1980-1990): 253 patients. Nouv. Rev. Fr. Hematol. (1991) 33:201–203.
   PubMedGoogle Scholar
• BRUSAMOLINO E, CANAVARI A, SALVANESCHI L, MERANTE S, BERNASCONI C: Efficacy trial of Pipobroman in essential thrombocythemia: a study of 24 patients. Cancer Treat Reports (1984) 68:1339–1342.
   PubMedGoogle Scholar
• MAZZUCCONI MG FRANCESCONI M, CHISTOLINI A et al: Pipobroman therapy of essential thrombocythemia. Scand. j Haematol (1986) 37:306–309.
   PubMedGoogle Scholar
• LENGFELDER E, GRIESSHAMMER M, HEHLMANN R: Interferon-alpha in the Treatment of Essential Thrombocythemia. Leuk. Lymphoma (1996) 22 (Suppl. 0:135–142.
   Google Scholar
• ELLIOT MA, TEFFERI A: Interferon-a therapy in Polycythaemia Vera and Essential Thrombocythemia. Semin. Thromb. Hemostas. (1997) 23:463–472.
   PubMed Web of Science ®Google Scholar
• GRIESSHAMMER M, BERGMANN L, HAFNER M et al.: Treatment and clinical course of essential thrombo-cythemia (LT): preliminary results of a prospective multicenter trial. Blood (1998) 92 (Suppl. 1):423a. Abstract 1750.
   Google Scholar
• GILBERT HS: long term treatment of myrloprolofera-tive disease with Interferon-alpha-2b: feasibility and efficacy. Cancer (1998) 83:1205–1213.
   PubMed Web of Science ®Google Scholar
• BENTLEY M, TAYLOR K, GRIGG A et al.: Long-term interferon-alpha-2a does not induce sustained hematologic remission in younger patients with essential thrombocythemia. Leuk. Lymphoma (1999) 36:123–128.
   PubMed Web of Science ®Google Scholar
• GRIESSHAMMER M, BERGMANN L, PEARSON TC: Fertility, pregnancy and the management of myeloproliferative disorders. Bailliere's Clinical Haematology (1998) 11:859–874.
   PubMedGoogle Scholar
• PESCATORE SL, LINDLEY C: Anagrelide: a novel agentfor the treatment of myeloproliferative disorders. Exp. Opin. Pharmacother. (2000) 1 (3):537–546.
   PubMedGoogle Scholar
• TEFFERI A, SILVERSTEIN MN, PETITT RM, MESA RA, SOLBERG LA Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications. Semin. Thromb. Hemost. (1997) 23:379–383.
   PubMed Web of Science ®Google Scholar
• PETITT RM, MURRAY N, SILVERSTEIN MN et al.: Anagre-lide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin. Hematol (1997) 34:51–54.
   PubMed Web of Science ®Google Scholar
• GRIESSHAMMER M, BANGERTER M, VAN VLIET HHDM, MICHIELS JJ: Aspirin in essential thrombocythemia: status quo and quo vadis. Semin. Thromb. Hemost. (1997) 23 :371–377.
   PubMed Web of Science ®Google Scholar
• WILLOUGHBY S, PEARSON TC: The use of aspirin in polycythemia vera and primary thrombocythemia. Blood Reviews (1998) 12:12–22.
   PubMed Web of Science ®Google Scholar
• TARTAGLIA AP, GOLDBERG JD, BERK PD, WASSERMAN LR: Adverse effects of antiaggregating therapy in the treatment of polycythemia vera. Semin. Hematol. (1986) 23:172–176.
   PubMed Web of Science ®Google Scholar
• ROCCA B, CIABATTONI G, TARTAGLIONE R et al.:Increased thromboxane biosynthesis in essential thrombocythemia. Thromb. Haemost. (1995) 74:1225–1230.
   PubMed Web of Science ®Google Scholar
• RANDI ML, ROSSI C, FABRIS F GIROLAMI A: Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy - a follow-up study in 68 patients. Clin. Appl. Thromb. Hemost. (2000) 6:31–35.
   PubMedGoogle Scholar
• TEFFERI A, SOLBERG LA, SILVERSTEIN MN: A CLINICAL UPDATE IN POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEM1A. Am. J. Med. (2000) 109:141–149.
   PubMed Web of Science ®Google Scholar
• STOREN EC, PEREIRA DL, FONSECA R, PETITT RM, TEFFERI A: Long-term use of anagrelide in young patients with essential thrombocythemia. Blood (1999) 94 (Suppl. 1):701a. Abstract 3096.
   Google Scholar